Market research
LMNX Defiance Daily Target 2x Long LMND ETF
NASDAQ USD Healthcare
Latest close
As of 27 Aug 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- 73.83
- Analyst target
- 37
- Dividend yield
- 1.0%
- Beta
- 0.0
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- ISIN
- US55027E1029
- Market cap
- 2B
- P/E ratio
- 73.83
- Analyst target
- 37
- Dividend yield
- 1.0%
- Beta
- 0.0
About
About Defiance Daily Target 2x Long LMND ETF
The fund is an actively managed exchange traded fund ("ETF") that attempts to achieve two times (200%) the daily percentage change in the share price of the Underlying Security by employing derivatives, namely swap agreements and/or listed options contracts. The fund manager has adopted a policy to have at least 80% exposure to financial instruments with economic characteristics that should perform 2X the daily performance of the Underlying Security"s shares. The fund is non-diversified.
Research context
Defiance Daily Target 2x Long LMND ETF appears in PyInvesting’s ETF catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the LMNX discussion.
5 years, 6 months ago
Luminex Corporation is currently in a long term uptrend where the price is trading 23.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.
Luminex Corporation's total revenue rose by 23.1% to $111M since the same quarter in the previous year.
Its net income has dropped by 92.9% to $239K since the same quarter in the previous year.
Finally, its free cash flow grew by 116.9% to $5M since the same quarter in the previous year.
Based on the above factors, Luminex Corporation gets an overall score of 4/5.